Development and Validation of Stability Indicating RP-HPLC Method for Assay of Mycophenolic Acid in Tablet Dosage Form
Pravin J. Kuwar, Sunila A. Patil*, Sunil P. Pawar*
Department of Pharmaceutical Quality Assurance, P.S.G.V.P. M’s, College of Pharmacy,
Shahada, 425409, Maharashtra, India.
*Corresponding Author E-mail: pravinjrajput12@gmail.com
ABSTRACT:
One of the most popular analytical methods for the separation, identification, and measurement of pharmaceutical substances is High Performance Liquid Chromatography (HPLC). The concepts, kinds, method development, and validation elements of HPLC are the main topics of this review, with a particular focus on the analysis of mycophenolic acid (MPA), a significant immunosuppressive medication. The mechanics of separation for several chromatographic modes, including as adsorption, ion-exchange, and size-exclusion chromatography, are covered. The review focuses on various reported RP-HPLC and HPLC-MS/MS techniques for biological matrices, pharmaceutical dosage forms, and bulk MPA quantification. A summary of important analytical parameters is provided, including mobile phase composition, column selection, flow rate, detection wavelength, linearity, accuracy, precision, limit of detection (LOD), and limit of quantification (LOQ). To guarantee specificity and dependability, stability-indicating techniques and forced degradation investigations are also emphasised. In order to guarantee method robustness and reproducibility, validation requirements are described in accordance with ICH guidelines. Researchers and analysts in pharmaceutical quality control and bioanalytical studies may find this review's thorough overview of HPLC method development and its use in the quantitative detection of mycophenolic acid helpful.
KEYWORDS: HPLC, Mycophenolic acid, RP-HPLC, Method development, Validation, Stability-indicating method.
INTRODUCTION:
A range of physico-chemical separation methods that share the distribution of a component between a mobile phase and a stationary phase are collectively referred to as "chromatography."The physical states of these two phases are used to categorise the different chromatographic processes. Tswett is credited with discovering chromatography as he was the first to separate and analyse leaf pigments on a polar solid phase in 1903. The distribution between a solid stationary and a liquid mobile phase was the only chromatographic use in the ensuing years (Liquid Solid Chromatography, LSC). Izmailov and Schreiber established the principles of Thin Layer Chromatography (TLC) in 1938. In 1958, Stahl improved this process and created the current approach. The idea of theoretical plates, which was derived from the theory of distillation processes, was put out by Martin and Synge in their famous 1941 work as a formal way to gauge the effectiveness of the chromatographic process.1,2
One of the most crucial instruments in analytical chemistry today, along with gas chromatography, is High Performance Liquid Chromatography (HPLC), which was developed from classical column chromatography. When it became feasible to create columns with packing materials composed of tiny beads (10 μm) and run them under high pressure, the HPLC process took off. The foundational works of Horvath, Knox, Scott, Snyder, Guiochon, Mockel, and others are essential to the development of HPLC and the theoretical comprehension of the separation processes. Small, Stevens, and Bauman presented Ion Chromatography (IC) as a novel analytical technique in 1975. Ion chromatography quickly developed from a novel method of detecting a small number of specific inorganic anions and cations to a flexible analytical method for ionic species in general.1,2
High efficiency separator columns with particle sizes ranging from 5 to 8μm were developed in the 1980s, leading to a notable decrease in analysis time. Additionally, ion-pair process-based separation techniques were developed as an alternative to ion-exchange chromatography since they enable the separation and measurement of both anions and cations. The goal of column development since the early 1990s has been to offer stationary phases with unique selectivity.3
The adsorption process used in HPLC is dynamic. Analyte molecules often interact with the surface adsorption sites as they pass through the porous packing beads. The various forms of adsorption forces may be incorporated into the retention process, depending on the HPLC mode. In reversed-phase (RP) separations, hydrophobic (non-specific) interactions predominate. In normal phase (NP), dipole-dipole (polar) interactions predominate. In ion exchange chromatography, ionic interactions are what cause retention. These exchanges are all competitive. The eluent molecules and analyte molecules are vying for the adsorption sites. Thus, the surface is affected by the stronger analyte molecules. The analyte will stay on the surface longer if the eluent contact is weaker. Another example is size-exclusion chromatography, or SEC. The mixture is separated according to the molecular size of its constituent parts. The fundamental idea behind SEC separation is that larger molecules have a lower chance of penetrating the adsorbent pore region. Therefore, the molecule will be maintained less if it is larger.3
Types of HPLC:4
There are many ways to classify liquid column chromatography. If this classification is based on the nature of the stationary phase and the separation process, three modes can be specified.
Adsorption chromatography:
The separation process is based on repeated adsorption-desorption processes, and the stationary phase is an adsorbent (such as silica gel or any other silica-based packing).
Ion-exchange chromatography:
The ionically charged surface of the stationary bed is charged in opposition to the ions in the sample. Ionic or ionisable samples are nearly always employed with this method. It will take longer to elute if the sample has a higher charge since it will be more drawn to the ionic surface. Elution time is controlled by both pH and ionic strength in the mobile phase, which is an aqueous buffer.
Size exclusion chromatography:
The column is filled with material having precisely controlled pore sizes, and the sample is simply screened or filtered according to its solvated molecular size. Larger molecules are rapidly washed through the column smaller molecules penetrate inside the porous of the packing particles and elute later. This technique is also called gel filtration or gel permeation chromatography.
HPLC as compared with the classical LC technique is characterized by:
· High resolution
· Small diameter (4.6mm), stainless steel, glass or titanium columns
· Column packing with very small (3, 5 and 10μm) particles
· Relatively high inlet pressures and controlled flow of the mobile phase
· Continuous flow detectors capable of handling small flow rates and detecting very small amount
· Rapid analysis
Schematic diagram of HPLC System: 5,6
The validation of a stability-indicating HPLC technique takes up most of the analytical development effort. The primary active drug, any reaction contaminants, all accessible synthetic intermediates, and any degradants are to be separated and quantified using the HPLC method. When developing a method, mass balance should always be taken into account. In general, it should be determined whether the area percent method (peak area normalisation) and the weight percent method (on a dry basis) are producing comparable results for a drug substance method, and whether peak area normalisation and the assay method (based on label claim) are producing comparable results for a drug product method. The existence of co-eluting impurities, contaminants with various response factors, or insufficient elution of all impurities in the sample may be indicated if a bias is found between HPLC area percent (peak area normalisation) and HPLC weight percent (assay). It should be noted that analytical chemists that work with the API typically utilise HPLC area percent and weight percent nomenclature to challenge the method and evaluate its capability for measuring the analytes under typical operating conditions.
In their Validation for analytical FDA guidance document, the International Conference on Harmonisation (ICH) defined validation protocols as "validated quantitative analytical methods that can detect the changes with time in the chemical, physical, or microbiological properties of the drug substance and drug product, and that are specific so that the contents of active ingredient, degradation products, and other components of interest can be accurately measured without interference"7,8. Many chromatographers must construct an HPLC separation on a daily basis, and after the method is finalised, it is validated by a series of trials. The procedures listed above are frequently followed in the development of HPLC methods. The development of methods is based on a number of factors. Nowadays, there is a solid practical understanding of chromatographic separation and how it changes depending on the sample and experimental conditions. Most of the time, a few experiments may easily obtain the needed separation. A solid method development plan should only call for the number of experimental runs required to produce the desired outcome. Nonetheless, technique creation ought to be as straightforward as feasible. The steps will be covered in the same sequence as they would be examined when developing a method. The reasoning will be demonstrated. By concentrating on creating an HPLC technique that indicates stability for similar compounds (impurities). However, the majority of alternative HPLC techniques will be able to use the same concepts.
An immunosuppressive medication called mycophenolic acid (MPA) is used to treat autoimmune diseases and prevent organ transplant rejection.9 MPA is given as mycophenolate mofetil (MP) to increase its oral bioavailability.10 During first-pass metabolism, an oral dose of MP is quickly hydrolysed to mycophenolic acid (MPA), which is then further broken down into two minor metabolites: phenolic glucoside of MPA and acyl glucuronide (AcMPAG). MPA has a strong affinity for plasma proteins, primarily human serum albumin (97–99%).11
Structure of Mycophenolic Acid:
MPA is frequently used in conjunction with prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) in the early post-transplant phase12. The enzyme inosine monophosphate dehydrogenase, which regulates the rate of guanine monophosphate synthesis in the de novo pathway of purine synthesis utilised in B and T cell proliferation, is inhibited by MPA.13
MATERIALS AND METHODS:
CONCLUSION:
For the precise measurement of mycophenolic acid in biological and pharmaceutical materials, HPLC is a reliable and popular analytical method. High precision, sensitivity, and dependability are demonstrated by several approved techniques, such as RP-HPLC and HPLC-MS/MS. The quality and repeatability of results are guaranteed by the use of stability-indicating techniques and ICH validation requirements. This study offers a succinct resource for the creation and verification of efficient mycophenolic acid analytical techniques.
ACKNOWLEDGMENTS:
The facilities and assistance required to do this review study were provided by their respective institutions, for which the authors are thankful. The authors further thank all the scientists and researchers whose important work in the fields of mycophenolic acid analysis and HPLC has been referenced in this review. Their efforts have been crucial to this article's effective compilation.
REFERENCES:
1. Skoog. D. A, Holler. F. G, Nieman. T. A. Principles of Instrumental Analysis. 5th Edition, Thomson Brooks/Cole Asia Pvt. Ltd., Singapore. 2004, 4-7.
2. Lloyd R. S, Kirkland.J. J, John W. Dolan. Introduction To Modern Liquid Chromatography, Third Edition, 2007, 88-553.
3. Willard. H. H, Meritt, L. L, Dean, J. A, Settle. F. A. Instrumental Methods of Analysis. 7th Edition, CBS Publishers and Distributors, New Delhi. 8-10
4. Chatwal. G. R, Anand. S. K. Instrumental Methods of Chemical Analysis. 5th Edition, Himalaya Publishing House, New Delhi. 2007: 2.624-2.629
5. Cione P.A, EdivanTonhi and Paulo Silva; Stability Indicating Method, Bioagri laboratories, Brazil,1- 30
6. Ahuja. S, Rasmussen. H, HPLC Method Development for Pharmaceutical Elsevier Academic Press. 2007: 13-43
7. Braun R.D., Introduction to Instrumental Analysis, 1st Edition, Mc Grawhill Book Company. 1987: 5- 7.
8. Fifield.W. F, Kealey.D; Principles and Practice of Analytical Chemistry, Fifth Edition, Blackwell Science Ltd. 2000: 80-83
9. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil (MPM) for the treatment of acute and chronic steriod–refractory graft– versus–host disease. Ann Hematol. 2005; 84: 681-5.
10. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit. 1995; 17: 681-4
11. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem. 1995; 41(7): 1011-7.
12. D.C. Cronin 2nd, T.W. Faust, L. Brady, H. Conjeevaram, S. Jain, P. Gupta, J.M. Millis, Clin. Liver Dis. 2000; 4: 619.
13. H.W. Sollinger, Clin. Transplant. 2004; 18: 485.
|
Received on 09.05.2026 Revised on 30.05.2026 Accepted on 19.06.2026 Published on 10.07.2026 Available online from July 25, 2026 Asian Journal of Pharmaceutical Analysis. 2026; 16(3):244-248. DOI: 10.52711/2231-5675.2026.00038 ©Asian Pharma Press All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|